Several genetic diseases are triggered by nonsense mutations leading to the formation of truncated and defective proteins. Aminoglycosides have the capability to mediate a bypass of stop mutations during translation thus resulting in a rescue of protein expression. So far no attention has been directed to obesity-associated stop mutations as targets for nonsense suppression. Herein, we focus on the characterization of the melanocortin-4-receptor (MC4R) nonsense allele W16X identified in obese subjects. 
Introduction
Nonsense mutations cause a premature termination of protein biosynthesis and can disable the proper function of a gene. Approximately 10% of cases in human inherited diseases such as cystic fibrosis, diabetes insipidus, Hurler syndrome and muscle dystrophy are the consequence of nonsense mutations. [1] [2] [3] [4] Several in vitro and in vivo studies have demonstrated that aminoglycosides like amikacin, gentamicin and G-418 have the ability to suppress clinically relevant stop mutations leading to a fractional reactivation of protein expression and function. [5] [6] [7] [8] It is hypothesized that aminoglycosides bind to the ribosome and lower the accuracy of codon-anticodon interaction thus allowing the incorporation of a random amino acid at the mutated position. 9 Read-through of nonsense mutations depends on the sequence of the termination codon. In general, highest suppression efficiencies were demonstrated for the TGA codon, followed by TAG and TAA. 6, 8 In addition, the nucleotide context surrounding the stop signal affects suppression efficiencies. 6, 8 Beside the lack of oral bioavailability, the clinical application of aminoglycosides is limited because of adverse effects, including oto-and nephrotoxocity. 10, 11 Other non-aminoglycoside nonsense suppressors, like the oxadiazol compound PTC124 (Ataluren), or the peptide antibiotic negamycin with mild side effects might be alternative means of establishing nonsense suppression in humans. [12] [13] [14] Obesity has become a major health concern in the last decades since an excess body fat accumulation is often accompanied by complex disease traits like cardiovascular disorders, type 2 diabetes and certain forms of cancer. 15 Body weight is influenced by extensive interactions among environmental, psychosocial and genetic factors. 16 So far no attention has been addressed to obesity-associated nonsense mutations as targets for stop suppressor compounds. Several stop mutations were identified in genes that are critical for the hypothalamic control of energy balance. Premature stop codons in genes encoding prohormone convertase 1, leptin receptor, pro-opiomelanocortin (POMC) and melanocortin-4-receptor (MC4R) were identified in obese subjects demonstrating the impact of certain nonsense alleles on energy homeostasis. [17] [18] [19] [20] Herein, we focus on the characterization of the MC4R X16 gene variant, which was identified in two obese females heterozygous for the stop mutation. 21 A single-nucleotide substitution (G-A) changes the highly conserved tryptophan encoding triplet TGG to a premature TGA termination codon. In addition to W16X, further stop mutations exist in the human MC4R gene. The non-conserved Y35X (TAA) as the most common MC4R stop variant exhibits heterozygous genotype frequencies around 0.5% in obese people. 22 The MC4R is a 332 amino acid G-protein-coupled receptor mainly expressed in hypothalamic nuclei involved in the regulation of energy balance. 23 The naturally occurring MC4R agonist a-melanocyte-stimulating hormone (MSH) is generated by post-translational processing of the protein precursor POMC. 24 Activation of MC4R-signaling induces a reduction in energy intake and an elevation of energy expenditure thus resulting in negative energy balance and weight loss. 25, 26 The physiological importance of MC4R is demonstrated by several obese mouse models harboring lossof-function mutations in the Mc4r locus. 27, 28 Furthermore, MC4R mutations have turned out to be the most frequent cause for monogenic obesity since approximately 150 variants including frameshift, missense and nonsense mutations have been predominately detected in obese individuals. 29 In our report, we investigated whether the MC4R X16 is a target for nonsense suppression. In cell cultures overexpressing Mc4r
X16
, we applied the aminoglycoside G-418 and assessed plasma membrane expression and signaling properties. Very recently, Mul et al. 30 H-Adenin (Perkin Elmer, Boston, MA, USA). Cells were stimulated for 1 h with various concentrations of a-MSH and NDP-a-MSH respectively along with the phosphodiesterase inhibitor 1 mM isobutylmethylxanthine (Sigma, Deisenhofen, Germany). The reaction was stopped by adding cold trichloroacetic acid to the cells. 3 H-cAMP was purified using Dowex AG 1-X8-columns (Bio-Rad, Hercules, CA, USA). Radioactivity was assessed and receptor activity is expressed as counts per well. Sigmoidal dose response curves were generated using Prism 4 software (GraphPad, La Jolla, CA, USA).
For assessment of cell surface expression, HEK293 cells were seeded in 12-well dishes (6 Â 10 5 cells per well) coated with 0.1% (w/v) poly-D-lysine on the day before the transfection. Cells were transiently transfected with 2.5 mg Mc4r expression vector per well utilizing the calcium phosphate method (Profection, Promega, Mannheim, Germany) in concordance to the manufacturer's instructions. On the day after, the transfection cells were treated with 75 mg ml -1 G-418 (Invitrogen) for 24 h. After washing the cells with phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA), cells were fixed in 4% formaldehyde in PBS. Then cells were washed twice with PBS containing 0.1% BSA to remove residual formaldehyde. After blocking unspecific protein-binding sites with PBS containing 1% BSA, Xpress epitope tagged MC4R fusion proteins were detected by incubating cells with 1/2500 diluted mouse-derived anti-Xpress antibody (Invitrogen) in PBS containing 0.1% BSA. Cells were washed twice with PBS containing 0.1% BSA and blocked with PBS containing 1% Only when food intake was monitored mice were separated and singly housed for the duration of the experiment.
Cohort 2 (only indirect calorimetry).
Mice were housed in a specific pathogen-free animal facility with pelleted food (type M/Z, Ssniff: 53% energy from carbohydrate, 36% from protein and 11% from fat) and water ad libitum at 22 1C in a 12:12 h light-dark cycle. Animals were singly housed for their whole life span.
Weight, length and body composition measurements Weight development was monitored regularly beginning at the age of 21 days. Body length was measured in transiently chloroform-narcotized mice. Animals were carefully extended to their full length, always by the same experimenter and the snout-to-anus distance was determined. Abdominal body composition (lumbar vertebra 1-6) of dead animals was measured in a LaTheta micro computer tomography scanner (Aloka, Meerbusch, Germany). Adipose tissue was distinguished into visceral and subcutaneous fat depots.
Energy intake, energy assimilation and assimilation efficiency For food intake measurements, animals were singly housed on plastic grids for 1 week. Mice were adapted for 3 days to the new environment. Afterward food intake was monitored for the next 4 consecutive days. At the end of the experiment, feces were collected and food consumption was corrected for spillage. Food and feces samples were analyzed for their energy content in a bomb calorimeter (type 6300 Calorimeter, Parr, Frankfurt, Germany). Samples were dried in a heating cabinet until weight constancy. Afterward samples were homogenized and pressed to tablets. Energy intake (E in ), feces energy content (E out ), energy assimilation (E ass ) and assimilation efficiency were calculated as followed:
Rectal body temperature Rectal body temperature was assessed utilizing a precision thermometer (Almemo 2490, Ahlborn, Holzkirchen, Germany). Temperature of each individual was taken three times during 5 days and the mean value for each individual was calculated. The measurements were performed at the same time of day and by the same researcher.
Indirect calorimetry
Indirect calorimetry was performed in an open flow respiratory system to assess energy expenditure (Phenomaster, TSE Systems, Bad Homburg, Germany). Single mice were placed in metabolic cuvettes (volume B2.5 l) with food and water ad libitum at 22 1C for 3 days. The first 24 h were considered as acclimatization and were excluded from the analysis. Extracted air from the cuvette (flow rate 30 l h -1 ) was dried in a cooling trap and analyzed approximately every 6 min for O 2 and CO 2 content. Oxygen consumption, carbon dioxide production and energy expenditure were calculated as described previously. 32 Energy expenditure was calculated per hour. Values per hour were summated to assess daily energy expenditure.
Intraperitoneal glucose tolerance test
Before the glucose tolerance test mice were fasted for 6 h. Blood from the tail tip was analyzed with a whole blood monitor (FreeStyle Lite, Abbott, Wiesbaden, Germany) to determine blood glucose concentrations. Afterward mice received an intraperitoneal glucose load (2 g glucose kg -1 body weight). During the next 2 h blood was taken in regular intervals (15, 30 , 60 and 120 min) for blood glucose determinations. The total area under the curve was calculated by using Prism 4 software (GraphPad).
Hypothalamic gene expression
Hypothalami were dissected with a brain blocker to achieve a standardized tissue sampling. Tissue was snap frozen in liquid nitrogen and stored at À80 1C until RNA purification. RNA was extracted using Trisure reagent (Bioline, Luckenwalde, Germany) and integrity was confirmed by gel electrophoresis. (None of the RNA samples were contaminated with genomic DNA tested by PCR.) RNA was reverse transcribed with the Quantitect cDNA synthesis kit (Qiagen, Hilden, Germany). Quantitative real-time PCR was performed utilizing a SYBR Green supplemented SensiMix (Bioline) in accordance to the manufacturer's instructions. The efficiency of amplification was calculated based on 2 n dilution series standard curves (Realplex Cycler software, Eppendorf, Hamburg, Germany) and used to determine starting quantity of the templates. The geometric mean of two housekeeping genes (heat shock protein 90 and b-actin) was used for normalization of transcript quantities in each individual sample. The primer pairs listed in Table 1 were validated and used for quantitative reverse transcriptase-PCR.
Aminoglycoside treatment protocol Treatment consisted of dorsal subcutaneous injections either of gentamicin (Hexal, 34 mg kg À1 day À1 ) or amikacin (Sigma, 170 and 510 mg kg À1 day À1 ) solved in PBS 1 h before lights off. In the pre-treatment phase, animals were adapted to the handling procedure with control injections. Hereafter, all animals were switched to the aminoglycoside treatment. Treatment protocols are detailed in the result section and the corresponding figure legends.
Results

Functional characterization of Mc4r
X16 in vitro In a first approach, the plasma membrane expression of murine MC4R wt and MC4R X16 was investigated in transiently transfected HEK293 cells using a surface enzymelinked immunosorbent assay. The stop mutated variant MC4R X16 showed no surface expression under control conditions compared with MC4R wt (Figure 1a) . The administration of 75 mg ml -1 G-418 induced a significant restoration of MC4R X16 plasma membrane abundance whereas MC4R wt surface expression was unaffected by treatment ( Figure 1a) .
Cell signaling was characterized in a radiolabeled cAMP accumulation assay. In accordance to the surface enzymelinked immunosorbent assay under control conditions, the MC4R X16 showed a loss-of-function phenotype. The agonists a-MSH and NDP-a-MSH did not induce a remarkable cAMP production in MC4R X16 -expressing Cos7 cells ( Figure  1b ). In the presence of 75 mg ml -1 G-418, the signaling properties of MC4R X16 -expressing cells in response to a-MSH and NDP-a-MSH were reactivated (Figure 1c) . Taken together in cell culture experiments, the aminoglycoside G-418 caused a suppression of the obesity-associated stop mutation Mc4r X16 . Table 1 Primer pairs for quantitative real-time PCR Figure  2c ). The XhoI recognition site next to the W16X position allowed PCR/restriction digest-based identification of ES clones carrying the mutation of interest. One of five targeted clones was positive for the premature TGA codon (data not shown). Implantation of this clone into C57BL/6J blastocysts produced several F0-chimeras that, when mated with C57BL/6J mice, transmitted the mutated Mc4r gene to their F1-offspring. Heterozygous F1 males were crossed with RosaCre deleter mice to eliminate the loxP-flanked neo gene from the targeted Mc4r X16 locus in the germ line. Successful neo deletion in F2 generation was demonstrated by PCR-based verification of the remaining loxP sequence. Further genotyping of F3 progeny used for the phenotyping experiments was performed by detecting the loxP site and the silent mutation causing a XhoI restriction site close to the W16X mutation (Figures 2d and e) . Results for both genotyping strategies were always in concordance. Genotype distribution was in line with Mendelian inheritance. Sequencing confirmed the presence of the premature TGA codon in the Mc4r gene (Figure 2f ). G-418 for 24 h or cultured the same time in aminoglycoside-free medium. A radioactive cAMP accumulation assay was used to assess a-melanocyte-stimulating hormone (MSH) and NDP-a-MSH induced receptor activity (shown is one representative experiment performed in replicates). (Figures  3a and b) . Male Mc4r X16/X16 knock-in mice older than 6 month weighed 70% more than their wild-type litter mates.
The effect strength of the W16X mutation was more pronounced in female mice since weight increase in Mc4r X16/X16 females was nearly 100% in comparison with wild types.
Abdominal body composition of dead mice between 25 and 28 weeks of age was assessed by computer tomography. Increased body weight was mainly because of an increase in X16/wt knock-in mice demonstrated the presence of the stop mutation. The silent mutation generating the XhoI recognition site was located 5-bp downstream of the premature termination codon.
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visceral fat tissue (Figures 3c and d (Figures 3e and f) . In the second mice cohort used for the assessment of energy expenditure, animals were singly housed under specific pathogen-free conditions. Here, lean mass in Mc4r X16/X16 mice of both sexes was reduced compared with wild types (data not shown).
To examine whether mutant mice possessed abnormalities in body length, snout-to-anus distance was measured in the age of approximately 20 weeks. Mc4r X16/X16 knock-in mice were significantly longer compared with Mc4r wt/wt mice (Figures 4a and b) . As observed for the body weight phenotype, the effect on linear growth was intermediate in heterozygous Mc4r X16/wt animals. The effect size of the W16X stop mutation on body length was similar in both sexes approximately with 5% per Mc4r X16 allele.
Energy intake, energy assimilation and assimilation efficiency Energy intake, energy assimilation (defined as the amount of energy resorbed by the intestine epithelium) and assimilation efficiency of 20-week-old mice were measured by bomb calorimetry. Hyperphagia in Mc4r X16/X16 knock-in mice resulted in an increased energy intake (E in ) and energy assimilation (E ass ) in males as well as in females (Figures 5a-d) . Assimilation efficiency was unaffected (Figures 5e and f Energy intake (E in ), energy assimilation (E ass ) and assimilation efficiency. Food intake and feces production was monitored in mice singly housed for the duration (1 week) of the experiment. Food and feces samples were analyzed for their energy content by bomb calorimetry. Energy intake of male (a) and females (b) mice. Energy assimilation of male (c) and females (d) mice. Assimilation efficiency of male (e) and females (f) mice. Each dot represents one individual animal (n ¼ 6-7). (*Po0.05; **Po0.01; ***Po0.001, one-way analysis of variance (ANOVA) and HolmSidak post-hoc test).
of 6 weeks (Figures 6a and b) . At the age of 9 weeks, obese Mc4r X16/X16 of both sexes had a significant elevated daily energy expenditure compared with Mc4r wt/wt mice ( Figures  6c and d) . Respiratory quotient was unchanged between genotypes (data not shown).
At the age of 20 weeks, body temperature of male mice was determined with a rectal probe. No significant difference appeared between the three genotypes, but a slight trend toward a lowered rectal body temperature was seen in 
Hypothalamic gene expression
Expression of genes involved in the hypothalamic regulation of energy homeostasis was investigated in male mice at the age of 25-28 weeks by quantitative real-time PCR ( Figure  8 ). The orexigenic genes Npy and Agrp displayed a significant downregulation in Mc4r X16/X16 animals. In contrast, the anorexigenic Pomc was upregulated in mutant mice.
Mc4r transcript abundance in mutant Mc4r
X16/X16 mice was significantly increased compared with wild-type littermates.
Intraperitoneal glucose tolerance test
Obesity is often accompanied by impaired glucose homeostasis. 15 Here, we performed an intraperitoneal glucose tolerance test in 6-h food deprived mice at the age of 20 weeks. littermates resulting in an increased area under the curve. The effect was more pronounced in male mutants ( Figure 9 ).
Aminoglycoside treatment
Owing to putative severe side effects of G-418, 33 in a first therapeutic trial we tested whether subcutaneous gentamicin and amikacin injections can alleviate obesity of Mc4r X16/X16 knock-in mice. Both aminoglycosides were published as potent nonsense suppressors in vivo without evoking adverse effects. 5, 7 Male Mc4r X16/X16 and Mc4r wt/wt mice in the age of 36 weeks were adapted to the handling by saline injections for 2 days. Hereafter, all mice received 34 mg kg À1 day À1 Figure 6 Daily energy expenditure (DEE). Indirect calorimetry was used to determine metabolic rates of Mc4r wt/wt and Mc4r X16/X16 mice. Animals were housed 3 days in metabolic cages. Energy expenditure per animal for males (n ¼ 5-7) (a) and females (n ¼ 5-7) (b) in the age of 6 weeks; males (n ¼ 9-10) (c) and females (n ¼ 5-8) (d) in the age of 9 weeks. Each dot represents the value for one individual animal. Numbers below genotypes indicate body weight of the respective group with s.d. (**Po0.01; ***Po0.001, Student's t-test). Figure 7 Body temperature of male mice in the age of around 20 weeks. Body temperature was assessed by a precision thermometer with a rectal probe. Measurements were performed always at the same time of day (around 1100 hours). Each dot represents one individual animal (n ¼ 6-10).
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gentamicin 1 h before the dark phase. No amelioration of obesity was observed during the 7-day gentamicin treatment. Both genotypes showed a slight reduction in body weight (B3%) (Figures 10a and b) .
In a next step, we tested amikacin in adult Mc4r
and Mc4r wt/wt females at the age of 42 weeks. In the pretreatment phase, mice were adapted to handling by daily PBS injections for 1 week. Hereafter, all mice received 170 mg kg À1 day À1 amikacin. After 13 days, we increased the dose to 510 mg kg À1 day À1 . No reduction of obesity was observed during the treatment period (Figures 11a and b) . The treatments were well tolerated by the mice.
Discussion
Nonsense suppressors such as aminoglycosides have the property to induce a read-through at premature termination codons leading to a partial rescue of protein expression. Up to now published studies did not address obesityassociated stop mutations as targets for nonsense mutation bypass therapy. To close this gap, we focused on the human obesity-associated MC4R stop mutation W16X. 21 We inserted the stop mutation into the murine Mc4r gene and studied the function of Mc4r X16 in a cell culture-based in vitro system. In addition, we established a new Mc4r 27, 35 Quantification of abdominal body composition revealed that weight gain was due to an increase in visceral fat mass. Interestingly, differences in body composition were identified in the two cohorts used for this study, which might be explained by different housing conditions suggesting that environmental factors like pathogen status, gut microflora and single/group housing affect obesity symptoms of Mc4r-deficient mice. X16/X16 mice (n ¼ 4) were adapted for 1 week to the handling procedure by phosphate-buffered saline (PBS) injections (day À7 to day 0). At day 0, all animals received once daily a single amikacin (in PBS) injection in the indicated dose for 19 days. At day 19, all animals were switched back to PBS. During the treatment, body weight (a) and food intake (b) was monitored. Each point represents the mean value with s.d.
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As obesity is the consequence of a positive energy balance, we monitored energy intake and energy assimilation as well as body temperature and energy expenditure. Homozygous mutants had a higher energy intake and assimilation than wild-type mice. The assimilation efficiency was unaffected demonstrating that increased energy assimilation is solely due to hyperphagia and not to a nutrient resorption abnormality in mutant mice.
Several studies demonstrated that MC4R agonists not only inhibit energy intake but also stimulate energy expenditure. 25, 26 In Mc4r-deficient mice, one should therefore expect a lowered metabolic rate. Previous studies, however, reported conflicting data on this issue. 26, 36, 37 The analysis of metabolic rates in obese animal models is complicated by the fact that the rate of energy expenditure increases as a function of body weight. There is an ongoing debate how to adjust for differences in body weights when comparing metabolic rates in lean and obese individuals. 38 We here aimed to circumvent this problem by analyzing energy expenditure in young pre-obese mice. X16/X16 knock-in mice, although in vivo studies have demonstrated the nonsense suppressor potency of these aminoglycosides. 5, 7, 49 Several (interacting) factors can be responsible for the absence of a weight-reduction. We did not test amikacin in cell culture therefore it might be possible that the compound is per se ineffective on the W16X stop mutation explaining the result in the in vivo approach. On the other hand, gentamicin can reactivate MC4R W16X in vitro 34 but failed to do so in vivo suggesting other explanations for the absence of an anti-obesity effect of the administration. The protocol of aminoglycoside treatment is fundamental for the efficiency of nonsense suppression. 5 Hence, optimization of drug dosing/administration may be of benefit to reactivate Mc4r X16 in vivo. Additionally, we cannot exclude a transient rescue of MC4R function in response to aminoglycosides on energy intake or energy expenditure, which would only be detectable during the first few hours after injection without affecting longterm energy balance. The aminoglycoside treatments were performed with adult mice when obesity is already severely developed. It seems worthwhile to explore the preventive therapeutic potential of nonsense suppression in younger pre-obese knock-in mice.
Several publications demonstrate a low penetration rate of gentamicin and amikacin across the blood-brain barrier. [50] [51] [52] The arcuate nucleus (ARC) of the hypothalamus is close to the median eminence, a circumventricular organ with an incomplete blood-brain barrier. Experiments with tracer substances suggest that neurons in the ARC are located outside of the blood-brain barrier whereas hypothalamic areas with high levels of Mc4r expression like the paraventricular nucleus appear to be protected by the blood-brain barrier. 23, 53 Until now, we did not perform pharmacokinetic studies but based on published observations amikacin/gentamicin concentrations in Mc4r-expressing sites after peripheral injections might be below effective concentrations because of the marginal penetration rate of aminoglycosides into brain tissue.
In future experiments, we will concentrate on optimization of aminoglycoside treatment protocols. Beside modifications of drug dosing, we will perform intracerebroventricluar canulations to directly supply Mc4r-expressing sites in the brain with nonsense suppressor drugs. Moreover, the application of non-aminoglycoside stop suppressors with other chemical properties such as negamycin and PTC124 appear promising to induce nonsense suppression in vivo. 12, 14 In summary, we demonstrated in cultured cells that the Mc4r X16 allele is per se prone to aminoglycoside-mediated read-through. We therefore generated a Mc4r X16 knock-in mouse line suitable for the in vivo evaluation of stop suppressor drugs. The mouse line showed a multitude of obesity symptoms that are perfectly in line with characteristics of other Mc4r-deficient animal models. Obesity as a quantitative trait is a simply accessible phenotype to evaluate nonsense suppression in vivo. In future experiments with the Mc4r X16 knock-in mouse model will be instrumental to establish nonsense suppression for an obesity-associated target gene expressed in the central nervous system.
